The implementation of the deregulation policy in Pakistan’s pharmaceutical sector, facilitated by the Special Investment Facilitation Council (SIFC) had been regarded as a significant step towards economic progress.
This policy has led to a remarkable increase in profits within the sector, which surged by 210%, reaching an impressive 13.5 billion Pakistani rupees.
The profits of the three largest companies in the sector have witnessed extraordinary growth, ranging from 44% to an astounding 339%. In 2024, the total revenue for the pharmaceutical sector rose by 21.1%, reaching 196.8 billion rupees.
Not only has deregulation improved the availability of medicines, but it has also led to a rise in the production of essential drugs like Panadol. This policy has brought greater transparency in drug pricing, enhanced competition, and provided access to quality medicines for the public.
The deregulation initiative is encouraging companies to invest in new drug research, which is expected to improve the quality of medicines further. Additionally, it ensures the prevention of substandard and overpriced drugs in the market.
With these positive developments, Pakistan’s pharmaceutical industry has become more attractive to investors, and the prospects for international investment have been significantly boosted.
